United Therapeutics Corporation

NasdaqGS:UTHR 株式レポート

時価総額:US$16.6b

United Therapeutics マネジメント

マネジメント 基準チェック /24

United Therapeuticsの CEO はMartine Rothblattで、 Jan1996年に任命され、 の在任期間は 28.83年です。 の年間総報酬は$ 16.96Mで、 8.7%給与と91.3%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の1.49%を直接所有しており、その価値は$ 248.65M 。経営陣と取締役会の平均在任期間はそれぞれ15.6年と22.2年です。

主要情報

Martine Rothblatt

最高経営責任者

US$17.0m

報酬総額

CEO給与比率8.7%
CEO在任期間28.8yrs
CEOの所有権1.5%
経営陣の平均在職期間15.6yrs
取締役会の平均在任期間22.2yrs

経営陣の近況

Recent updates

United Therapeutics: One To Believe In Despite Competitive Threats

Nov 14

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 18
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

Sep 27
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

United Therapeutics: Economics Support Compounding Ability

Aug 20

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jul 26
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Jul 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

Jun 13
United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

United Therapeutics: Exciting Company With A Big Problem

Jun 02

We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

Apr 05
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects

Mar 20

Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Mar 15
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

Jan 02
Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Dec 08
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Nov 16
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Sep 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Aug 07
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

May 22
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

Apr 25
Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

Feb 06
We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jan 16
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 20
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

United Therapeutics: Ability To Expand Tyvaso To Large IPF Market

Aug 24

Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Aug 04
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

CEO報酬分析

United Therapeutics の収益と比較して、Martine Rothblatt の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

US$1b

Jun 30 2024n/an/a

US$1b

Mar 31 2024n/an/a

US$1b

Dec 31 2023US$17mUS$1m

US$985m

Sep 30 2023n/an/a

US$900m

Jun 30 2023n/an/a

US$872m

Mar 31 2023n/an/a

US$728m

Dec 31 2022US$5mUS$1m

US$727m

Sep 30 2022n/an/a

US$707m

Jun 30 2022n/an/a

US$631m

Mar 31 2022n/an/a

US$687m

Dec 31 2021US$4mUS$1m

US$476m

Sep 30 2021n/an/a

US$462m

Jun 30 2021n/an/a

US$471m

Mar 31 2021n/an/a

US$405m

Dec 31 2020US$5mUS$1m

US$515m

Sep 30 2020n/an/a

US$469m

Jun 30 2020n/an/a

US$430m

Mar 31 2020n/an/a

US$528m

Dec 31 2019US$46mUS$1m

-US$104m

Sep 30 2019n/an/a

-US$92m

Jun 30 2019n/an/a

-US$118m

Mar 31 2019n/an/a

-US$150m

Dec 31 2018US$16mUS$1m

US$589m

Sep 30 2018n/an/a

US$543m

Jun 30 2018n/an/a

US$713m

Mar 31 2018n/an/a

US$484m

Dec 31 2017US$37mUS$1m

US$418m

報酬と市場: Martineの 総報酬 ($USD 16.96M ) は、 US市場 ($USD 12.66M ) の同規模の企業の平均を上回っています。

報酬と収益: Martineの報酬は過去 1 年間で 20% 以上増加しました。


CEO(最高経営責任者

Martine Rothblatt (69 yo)

28.8yrs

在職期間

US$16,958,057

報酬

Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Martine Rothblatt
Founder28.8yrsUS$16.96m1.49%
$ 248.7m
Michael Benkowitz
President & COO8.4yrsUS$9.81m0.0058%
$ 960.6k
James Edgemond
CFO & Treasurer11.8yrsUS$6.05m0.018%
$ 3.0m
Paul Mahon
Executive VP28.8yrsUS$5.15m0.082%
$ 13.7m
Dewey Steadman
Head of Investor Relationsno dataデータなしデータなし
Holly Hobson
Associate Vice President of Human Resourcesno dataデータなしデータなし
Kevin Gray
Senior Vice President of Strategic Operations & Logisticsno dataデータなしデータなし
Patrick Poisson
Executive VP of Technical Operations15.6yrsデータなしデータなし
Leigh Peterson
Executive Vice President of Product Development & Xenotransplantationno dataデータなしデータなし
Gil Golden
Senior VP & Chief Medical Officerno dataデータなしデータなし

15.6yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: UTHRの経営陣は経験豊富で経験豊富です(平均在職期間は15.6年)。


取締役

名称ポジション在職期間報酬所有権
Martine Rothblatt
Founder28.8yrsUS$16.96m1.49%
$ 248.7m
Samuel Thier
Member of the Scientific Advisory Boardno dataデータなしデータなし
Raymond Kurzweil
Independent Director22.8yrsUS$457.60k0.027%
$ 4.5m
Louis Sullivan
Independent Director & Member of the Scientific Advisory Board22.2yrsUS$471.54k0.029%
$ 4.9m
Raymond Dwek
Independent Director & Member of the Scientific Advisory Board22.8yrsUS$456.54k0.0039%
$ 652.6k
Christopher Patusky
Independent Vice Chairman & Lead Independent Director22.1yrsUS$532.60k0.0045%
$ 745.8k
Christopher Causey
Independent Director21.3yrsUS$481.54k0.0082%
$ 1.4m
Robert Bourge
Member of the Scientific Advisory Boardno dataデータなしデータなし
Thomas Thompson
Independent Director22.8yrsUS$456.54k0.050%
$ 8.4m
Magdi Yacoub
Member of the Scientific Advisory Boardno dataデータなしデータなし
Judy Olian
Independent Director9.4yrsUS$488.66k0.013%
$ 2.1m
Richard Giltner
Independent Director15.6yrsUS$513.66k0.039%
$ 6.5m

22.2yrs

平均在職期間

76yo

平均年齢

経験豊富なボード: UTHRの 取締役会 は経験豊富で 経験豊富 です ( 22.2年の平均在任期間)。